Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats

Hypertension Research

Volumn 28, Issue 12, 2005, Pages 1017-1023

  Shokoji, Takatomi ^a   Fujisawa, Yoshihide ^a   Kiyomoto, Hideyasu ^a   Rahman, Matlubur ^a   Sun, Guang Ping ^a   Fan, Yu Yan ^a   Kimura, Shoji ^a   Kohno, Masakazu ^a   Abe, Youichi ^a   Nishiyama, Akira ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Amlodipine; Azelnidipine; Heart rate (HR); Renal sympathetic nerve activity (RSNA); Spontaneously hypertensive rats (SHR)

Indexed keywords

AMLODIPINE; AZELNIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; NITROPRUSSIDE SODIUM; PHENYLEPHRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; HEART RATE; HEMODYNAMICS; HYPERTENSION; KIDNEY NERVE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRESSORECEPTOR REFLEX; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYMPATHETIC TONE;

AMLODIPINE; ANIMALS; AZETIDINECARBOXYLIC ACID; BAROREFLEX; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; HEMODYNAMIC PROCESSES; KIDNEY; MALE; NITROPRUSSIDE; PHENYLEPHRINE; RATS; RATS, INBRED SHR; SYMPATHETIC NERVOUS SYSTEM; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 33644514960     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.28.1017     Document Type: Article

References (30)

1. Ogihara T, Hiwada K, Morimoto S, et al: Guidelines for treatment of hypertension in the elderly - 2002 revised version. Hypertens Res 2003; 26: 1-36.
2. Psaty BM, Heckbert SR, Koepsell TD, et al: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-625.
3. Furberg CD, Psaty BM, Meyer JV: Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
4. Leenen FH, Ruzicka M, Huang BS: Central sympathoinhibitory effects of calcium channel blockers. Curr Hypertens Rep 2001; 3: 314-321.
5. Yui Y, Sumiyoshi T, Kodama K, et al, Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group: Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181-191.
6. Iino Y, Hayashi M, Kawamura T, et al, Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators: Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res 2004; 27: 21-30.
7. Minami J, Ishimitsu T, Kawano Y, Matsuoka H: Effects of amlodipine and nifedipine retard on autonomic nerve activity in hypertensive patients. Clin Exp Pharmacol Physiol 1998; 25: 572-576.
8. Grassi G, Spaziani D, Seravalle G, et al: Effects of amlodipine on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Hypertension 1999; 33: 671-675.
9. Binggeli C, Corti R, Sudano I, Luscher TF, Noll G: Effects of chronic calcium channel blockade on sympathetic nerve activity in hypertension. Hypertension 2002; 39: 892-896.
10. Hamada T, Watanabe M, Kaneda T, et al: Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. J Hypertens 1998; 16: 111-118.
11. Tsutamoto T, Tsutsui T, Maeda K, et al: Effects of long-acting calcium channel antagonists on neurohumoral factors: comparison of nifedipine coat-core with amlodipine. J Cardiovasc Pharmacol 2003; 41: S77-S81.
12. Eguchi K, Kario K, Shimada K: Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. Hypertens Res 2002; 25: 329-333.
13. Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T: Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003; 26: 201-208.
14. Koike H, Kimura T, Kawasaki T, et al: Azelnidipine, a long-acting calcium channel blocker with slow onset and high vascular affinity. Annu Rep Sankyo Res Lab 2002; 54: 1-64.
15. Arita M, Hashizume T, Tanigawa K, Yamamoto H, Nishio I: A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial. J Cardiovasc Pharmacol 1999; 33: 186-192.
16. Fujisawa Y, Mori N, Yube K, Miyanaka H, Miyatake A, Abe Y: Role of nitric oxide in regulation of renal sympathetic nerve activity during hemorrhage in conscious rats. Am J Physiol 1999; 277: H8-H14.
17. Shokoji T, Nishiyama A, Fujisawa Y, et al: Renal sympathetic nerve responses to tempol in spontaneously hypertensive rats. Hypertension 2003; 41: 266-273.
18. Shokoji T, Fujisawa Y, Kimura S, et al: Effects of local administrations of tempol and diethyldithio-carbamic on peripheral nerve activity. Hypertension 2004; 44: 236-243.
19. ++ channel blocker. Jpn J Pharmacol 1989; 51: 57-64.
20. Huang BS, Leenen FH: Sympathoinhibitory and depressor effects of amlodipine in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2003; 42: 153-160.
21. Frohlich ED, McLoughlin MJ, Losem CJ, Ketelhut R, Messerli FH: Hemodynamic comparison of two nifedipine formulations in patients with essential hypertension. Am J Cardiol 1991; 68: 1346-1350.
22. Noll G, Wenzel RR, Shaw S, Luscher TF: Calcium antagonists and sympathetic nerve activation: are there differences between classes? J Hypertens Suppl 1998; 16: S17-S24.
23. 2+ channel function and drug action. Trends Pharmacol Sci 1995; 16: 43-49.
24. 2+ channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther 1999; 291: 464-473.
25. 2+ channel (alpha1G) expressed in Xenopus oocytes. J Cardiovasc Pharmacol 2005; 45: 241-246.
26. 2+ channel blocking action of an antihypertensive drug, cilnidipine, in IMR-32 human neuroblastoma cells. Hypertens Res 2003; 26: 743-747.
27. Gao L, Wang W, Li YL, et al: Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase. Circ Res 2004; 95: 937-944.
28. Campese VM, Ye S, Zhong H, Yanamadala V, Ye Z, Chin J: Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am J Physiol Heart Circ Physiol 2004; 287: H695-H703.
29. Shinomiya K, Mizushige K, Fukunaga M, et al: Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells. J Int Med Res 2004; 32: 170-175.
30. Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T: Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol 2004; 43: 724-730.